Researcher
Matthias Gijsen
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Sep 2016 → Today
Projects
1 - 4 of 4
- Optimizing Antibacterial Dosing in Special Patient PopulationsFrom24 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Antibacterial dose optimisation based on augmented renal clearance in adult critically ill patients and selected pediatric patientsFrom1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Beyond optimising drug exposure: Pharmacodynamic models to bridge the gap between exposure and response to antimicrobial treatmentsFrom15 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- ANTIBACTERIAL DOSING IN SPECIAL PATIENT POPULATIONS WITH SEVERE BACTERIAL INFECTIONS: A PATIENT-ORIENTED AND COVARIATE-DRIVEN APPROACHFrom1 Oct 2016 → 30 Sep 2021Funding: BOF - Doctoral projects, BOF - doctoral mandates
Publications
11 - 20 of 30
- Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia(2022)
Authors: Matthias Gijsen, Johan Maertens, Katrien Lagrou, Stefanie Desmet, Erwin Dreesen, Willy Peetermans, Yves Debaveye, Isabel Spriet
- Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians(2021)
Authors: Lorenz Van der Linden, Matthias Gijsen, Karel Allegaert, Pieter Annaert, Jos Tournoy
Pages: 1020 - 1030 - Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine(2021)
Authors: Matthias Gijsen, Dirk Vlasselaers, Karel Allegaert
- ANTIBACTERIAL DOSING IN SPECIAL PATIENT POPULATIONS WITH SEVERE BACTERIAL INFECTIONS: A PATIENT-ORIENTED AND COVARIATE-DRIVEN APPROACH(2021)
Authors: Matthias Gijsen, Isabel Spriet, Yves Debaveye, Pieter Annaert
- Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid(2021)
Authors: Ruth Van Daele, Joost Wauters, Matthias Gijsen, Pieter Annaert, Yves Debaveye, Katrien Lagrou, Willy Peetermans
- Pharmacokinetic variability and target attainment of fluconazole in critically ill patients(2021)
Authors: Ruth Van Daele, Joost Wauters, Katrien Lagrou, Matthias Gijsen, Yves Debaveye
- Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis(2021)
Authors: Matthias Gijsen, Erwin Dreesen, Pieter Annaert, Yves Debaveye, Joost Wauters
- Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study(2021)
Authors: Matthias Gijsen, Erwin Dreesen, Ruth Van Daele, Pieter Annaert, Yves Debaveye, Joost Wauters
- Letter to the Editor regarding: Ceftriaxone exposure in patients undergoing extracorporeal membrane oxygenation(2021)
Authors: Matthias Gijsen, Pieter Annaert, Joost Wauters
- Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation(2021)
Authors: Ruth Van Daele, Erwin Dreesen, Matthias Gijsen, Yves Debaveye, Joost Wauters
Pages: 1234 - 1241